Skip to content
All posts

Our Journey Continues: Opening Access to Millions with Diabetes

Imagine a world where living with diabetes doesn’t mean living in fear of its worst complications. At Journey, we're making that vision a reality. Our mission is clear: to lead the way to better diabetes health, harnessing the power of predictive biomarker testing and precision medicine.

Our commitment to revolutionizing diabetes care is exemplified by our innovative screening technology, NaviDKD®. This advanced tool predicts an individual's risk for developing diabetes-related kidney disease (DKD) up to 12 years before any symptoms appear. Unlike current diagnostics that only identify existing kidney damage, NaviDKD offers a powerful, forward-looking perspective. This personalized risk assessment empowers individuals with the foresight needed to take proactive measures in safeguarding their long-term health.

Early detection and intervention are key to preventing complications and improving the quality of life for people with diabetes. This is why widespread screening among the diabetes population is paramount in our efforts to combat diabetes complications. However, access to innovative tools like ours shouldn't be a barrier. To address this, we have made it a primary goal to ensure NaviDKD is as accessible as it is effective, leading our focused efforts on securing health insurance coverage.

Over the past two years, our dedicated team has tirelessly navigated the complexities of the healthcare landscape. We've reached a significant milestone by securing a coveted CPT code through the American Medical Association (AMA) and establishing a fee schedule with the Centers for Medicare and Medicaid Services (CMS). This monumental achievement, effective January 1, 2024, represents not just a win for Journey but also a notable advancement for the entire diabetes community. The establishment of NaviDKD's CPT code and fee schedule is a critical step forward, paving the way for wider adoption and impact in diabetes care.

Our journey, however, doesn't end here. In the coming months, we are set to engage with managed care organizations nationwide to expand access to NaviDKD for millions. Additionally, we are preparing for a commercial launch in several states, bringing the power of prevention closer to you.

We invite you to join us in our mission. By signing up for our waitlist, sharing our story, raising awareness, and advocating for broader access to innovative tools like NaviDKD, you're playing a crucial role in empowering people to take proactive control of their health, free from the fear of complications. Your support in spreading the word is invaluable. 

If you're living with diabetes, check your eligibility now and join our growing VIP list to stay ahead in your health journey.

If you're a healthcare professional, join our KOL list to be the first to offer this innovative screening tool to your patients as soon as it becomes available in your area.

Together, we can shift the future of care.

About Journey Biosciences

Journey Biosciences is shifting the future of care through predictive innovations. Our flagship solution blends the precision of NaviDKD®, a clinically-validated predictive screening, with the AI-driven insights of Compass, offering up to 12 years of advanced diabetes-related kidney disease (DKD) detection and tailored intervention strategies. This groundbreaking approach improves patient outcomes, optimizes resource allocation, and reduces costs. Discover more about our transformative approach at

For media inquiries: